Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

Clinical trial NCT04545762 · RECRUITING

Trial details

NCT number: NCT04545762
Sponsor: C. Babis Andreadis
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Refractory Non-Hodgkin Lymphoma Burkitt Lymphoma Mantle Cell Lymphoma Follicular Lymphoma Lymphoplasmacytic Lymphoma Primary Mediastinal Large B Cell Lymphoma Diffuse Large B Cell Lymphoma Small Lymphocytic Lymphoma Transformed Lymphoma Non-Hodgkin Lymphoma

Start date: 2020-09-11
Primary completion: 2026-10-31
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.